Shyam Kalavar

564 total citations
5 papers, 121 citations indexed

About

Shyam Kalavar is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Shyam Kalavar has authored 5 papers receiving a total of 121 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Pulmonary and Respiratory Medicine, 3 papers in Oncology and 1 paper in Molecular Biology. Recurrent topics in Shyam Kalavar's work include Advanced Breast Cancer Therapies (2 papers), Cancer Immunotherapy and Biomarkers (2 papers) and HER2/EGFR in Cancer Research (1 paper). Shyam Kalavar is often cited by papers focused on Advanced Breast Cancer Therapies (2 papers), Cancer Immunotherapy and Biomarkers (2 papers) and HER2/EGFR in Cancer Research (1 paper). Shyam Kalavar collaborates with scholars based in United States, South Korea and Germany. Shyam Kalavar's co-authors include Eugene Schwartz, Lindsay Welch, Katherine L. Hunting, F. Stern, Julia A. Beaver, Soma Ghosh, Helen Longbottom, Richard Pazdur, Shenghui Tang and Laleh Amiri‐Kordestani and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Occupational and Environmental Medicine.

In The Last Decade

Shyam Kalavar

5 papers receiving 118 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shyam Kalavar United States	5	61	37	34	19	16	5	121
Felipe Silva Rodrigues United Kingdom	4	64 1.0×	20 0.5×	35 1.0×	14 0.7×	35 2.2×	6	135
Shaun Tiwari United States	3	112 1.8×	18 0.5×	20 0.6×	18 0.9×	33 2.1×	3	178
Samuel M. Niman United States	5	56 0.9×	40 1.1×	24 0.7×	9 0.5×	16 1.0×	15	76
Emerik Österlund Sweden	5	103 1.7×	64 1.7×	32 0.9×	10 0.5×	26 1.6×	14	146
Ania Sliwinski Australia	7	34 0.6×	32 0.9×	103 3.0×	6 0.3×	23 1.4×	8	145
Serena Corsetti Italy	8	55 0.9×	25 0.7×	34 1.0×	5 0.3×	28 1.8×	19	112
A. Martoni Italy	7	101 1.7×	26 0.7×	67 2.0×	18 0.9×	38 2.4×	23	153
Ángel Rodríguez United States	6	71 1.2×	77 2.1×	76 2.2×	13 0.7×	45 2.8×	23	152
Roi Weiser United States	8	48 0.8×	51 1.4×	37 1.1×	6 0.3×	12 0.8×	18	111
Sam Khan United Kingdom	6	31 0.5×	19 0.5×	26 0.8×	5 0.3×	25 1.6×	18	96

Countries citing papers authored by Shyam Kalavar

Since Specialization

Citations

This map shows the geographic impact of Shyam Kalavar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shyam Kalavar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shyam Kalavar more than expected).

Fields of papers citing papers by Shyam Kalavar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shyam Kalavar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shyam Kalavar. The network helps show where Shyam Kalavar may publish in the future.

Co-authorship network of co-authors of Shyam Kalavar

This figure shows the co-authorship network connecting the top 25 collaborators of Shyam Kalavar. A scholar is included among the top collaborators of Shyam Kalavar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shyam Kalavar. Shyam Kalavar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

5 of 5 papers shown

1.

Dilawari, Asma, Christy Osgood, Xin Gao, et al.. (2024). US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Locally Advanced or Metastatic Breast Cancer With PIK3CA / AKT1 / PTEN Alterations. Journal of Clinical Oncology. 42(34). 4103–4113. 13 indexed citations

2.

Mathieu, Luckson, Erin Larkins, A. K. Sinha, et al.. (2023). FDA Approval Summary: Atezolizumab as Adjuvant Treatment following Surgical Resection and Platinum-Based Chemotherapy for Stage II to IIIA NSCLC. Clinical Cancer Research. 29(16). 2973–2978. 27 indexed citations

3.

Narayan, Preeti, Asma Dilawari, Christy Osgood, et al.. (2023). US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer. Journal of Clinical Oncology. 41(11). 2108–2116. 34 indexed citations

4.

Gulley, James L., Jay A. Berzofsky, Marcus O. Butler, et al.. (2017). Immunotherapy biomarkers 2016: overcoming the barriers. Journal for ImmunoTherapy of Cancer. 5(1). 29–29. 16 indexed citations

5.

Hunting, Katherine L., Helen Longbottom, Shyam Kalavar, et al.. (1995). Haematopoietic cancer mortality among vehicle mechanics.. Occupational and Environmental Medicine. 52(10). 673–678. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact